LDS/Medical Tests/FoundationFocus CDxBRCA

FoundationFocus CDxBRCA

FoundationFocus™ CDxBRCA LOH is an assay that uses next-generation sequencing (NGS) for qualitative detection of BRCA1 and BRCA2 sequence alterations and genomic loss of heterozygosity (LOH) from formalin-fixed, paraffin-embedded (FFPE) ovarian tumor tissue. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious tumor BRCA variants (tBRCA-positive), who may be eligible for treatment with Rubraca (rucaparib).

Positive homologous recombination deficiency (HRD) status (defined as tBRCA-positive or LOH high) in ovarian cancer patients is associated with improved progression-free survival (PFS) from Rubraca maintenance therapy. See the RUBRACA product label for information about guiding therapy in specific clinical circumstances. This test is to be performed at Foundation Medicine, Inc., a single laboratory site, located at 150 Second Street, Cambridge, MA 02141.

  • This test is used to find BRCA1 and BRCA2 alterations in FFPE ovarian tumor tissue
  • The test is used in patients for whom Rubraca (rucaparib) is being considered
All pathogenic variants and insertions/deletions will have clinical interpretation.

No reportable variants were identified (Negative for mutation analyzed)

Next Generation Sequencing (NGS).

Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.

Germline BRCA1/BRCA2 testing.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login